CIK 0001472091
- Non-accelerated filer
- Smaller reporting company
PDS Biotechnology Corp
Sign in to watch- Ticker
- PDSB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 264231384
- Phone
- +1 800-208-3343
- Business address
- 303A COLLEGE ROAD EAST, PRINCETON, NJ, 08540
- Former names
- Edge Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-06-19 | MARCHIO ALBERT N II Chief Accounting & Adm Officer | Grant or award · Stock Option (Right To Purchase) | +83,334 | 83,334 | ||
| 2018-06-19 | BARER SOL J Director | Grant or award · Stock Option (Right To Purchase) | +40,000 | 40,000 | ||
| 2018-06-19 | Macdonald R. Loch Director | Grant or award · Stock Option (Right To Purchase) | +20,000 | 20,000 | ||
| 2018-06-19 | Crane Rosemary A Director | Grant or award · Stock Option (Right To Purchase) | +20,000 | 20,000 | ||
| 2018-06-19 | LOUGHLIN JAMES J Director | Grant or award · Stock Option (Right To Purchase) | +20,000 | 20,000 | ||
| 2018-06-19 | Spiegel Robert J. Director | Grant or award · Stock Option (Right To Purchase) | +20,000 | 20,000 | ||
| 2018-06-19 | Leuthner Brian A President and CEO | Grant or award · Stock Option (Right To Purchase) | +338,068 | 338,068 | ||
| 2018-06-19 | Saik Andrew Chief Financial Officer | Grant or award · Stock Option (Right To Purchase) | +166,001 | 166,001 | ||
| 2018-06-19 | Faleck Herbert J Chief Medical Officer | Grant or award · Stock Option (Right To Purchase) | +119,667 | 119,667 | ||
| 2018-06-19 | MIDDLEKAUFF W BRADFORD Senior VP, GC and Secretary | Grant or award · Stock Option (Right To Purchase) | +99,534 | 99,534 | ||
| 2018-06-19 | Wyant Alyssa SVP Regulatory Affairs | Grant or award · Stock Option (Right To Purchase) | +99,534 | 99,534 | ||
| 2018-03-23 | Conti Kurt G Director | Other disposition | −58,476 | 0 | ||
| 2018-03-22 | Macdonald R. Loch Chief Scientific Officer | Sale | −2,500 | $16.41 | $41K | 570,602 |
| 2018-03-21 | Macdonald R. Loch Chief Scientific Officer | Sale | −2,500 | $16.52 | $41K | 573,102 |
| 2018-03-20 | Macdonald R. Loch Chief Scientific Officer | Sale | −5,000 | $16.47 | $82K | 575,602 |
| 2018-03-19 | Macdonald R. Loch Chief Scientific Officer | Sale | −2,500 | $16.66 | $42K | 580,602 |
| 2018-03-02 | Leuthner Brian A President and CEO | Sale | −2,500 | $15.08 | $38K | 70,236 |
| 2018-03-01 | MIDDLEKAUFF W BRADFORD Senior VP, GC and Secretary | Grant or award · Stock Option (Right To Purchase) | +65,000 | 65,000 | ||
| 2018-03-01 | Faleck Herbert J Chief Medical Officer | Grant or award · Stock Option (Right To Purchase) | +90,000 | 90,000 | ||
| 2018-03-01 | BRENNAN DANIEL Chief Operating Officer | Grant or award · Stock Option (Right To Purchase) | +90,000 | 90,000 |
Page 9 of 18 · 346 trades